AZN
AstraZeneca · Nasdaq · UK/Sweden
Cap tier
Mega
Approx cap
$240.0B
Bull scenarios
23
Adverse scenarios
0
Other links
0
Modeled impact
unknown
0 explicit links; 23 public links lack move; 0 lack probability
Themes & clusters
From SRC_B Theme-Company Matrix
C10AI-discovered Drugs PipelineComparative genomics
Investment thesis
From SRC_B Company Master
Most AI-forward big pharma
Bull scenarios (23)
Predictions where this ticker benefits
| Pred | Role | Domain | Prediction | Predictor | Current | Move | Impact | Status |
|---|---|---|---|---|---|---|---|---|
| 245_011 | multi_vector | Biotech/Longevity | Colossal is spinning out a dozen companies each with massive potential | Peter Diamandis | 54.1% | unknown | unknown | pending |
| 245_005 | multi_vector | Biotech/Longevity | Countries will become customers to preserve endangered species via Colossal | Peter Diamandis | 52.9% | unknown | unknown | pending |
| 235_029 | multi_vector | Biotech/Longevity | Big pharma companies will transition into longevity business in next 3 years. | Peter Diamandis | 52.9% | unknown | unknown | pending |
| 235_027 | multi_vector | Biotech/Longevity | Longevity VC market expected to grow from $8.5B in 2024 to $12-18B in 2026. | Peter Diamandis | 46.5% | unknown | unknown | pending |
| 245_041 | multi_vector | Biotech/Longevity | Colossal will build a living lab in UAE in addition to Biovault | Ben Lamm | 45.0% | unknown | unknown | pending |
| 245_036 | multi_vector | Biotech/Longevity | Colossal will continue seeding and spinning out new companies from scientific discoveries | Ben Lamm | 45.0% | unknown | unknown | pending |
| 245_039 | multi_vector | Biotech/Longevity | Colossal has not yet started work on dinosaurs, corals, dragons or Pokemon | Ben Lamm | 45.0% | unknown | unknown | pending |
| 245_007 | multi_vector | Biotech/Longevity | Colossal will bring back the woolly mammoth | Ben Lamm | 44.9% | unknown | unknown | pending |
| 245_033 | multi_vector | Biotech/Longevity | Colossal will work to reintroduce all de-extincted species back into their environments | Ben Lamm | 44.3% | unknown | unknown | pending |
| 245_014 | multi_vector | Biotech/Longevity | Colossal has major announcements coming this year with a local government on productionizing cloning of endangered species | Ben Lamm | 41.3% | unknown | unknown | pending |
| 245_027 | multi_vector | Biotech/Longevity | Colossal DNA synthesis delivery will reach 20x the largest prior delivery by end of 2026 | Ben Lamm | 41.0% | unknown | unknown | pending |
| 245_006 | multi_vector | Biotech/Longevity | Colossal will productionize species development via biobanking, synthetic biology, automation, AI, computer vision and artificial wombs | Ben Lamm | 41.0% | unknown | unknown | pending |
| 245_026 | multi_vector | Biotech/Longevity | Colossal editing tech will be applicable to human healthcare (spun out/licensed) | Ben Lamm | 40.6% | unknown | unknown | pending |
| 245_015 | multi_vector | Biotech/Longevity | Colossal could theoretically create Pikachu (engineer novel designer organisms) | Ben Lamm | 40.6% | unknown | unknown | pending |
| 245_029 | multi_vector | Biotech/Longevity | IVF will be transformed by Colossal's hydrogel/microfluidics embryo tech and new grading scale | Ben Lamm | 40.6% | unknown | unknown | pending |
| 239_031 | multi_vector | Biotech/Longevity | Ben Lamb / Colossal could engineer a Pikachu-like creature | Ben Lamm | 40.6% | unknown | unknown | pending |
| 245_045 | multi_vector | Biotech/Longevity | Colossal considers Colossal platform core will stay focused on biodiversity and de-extinction | Ben Lamm | 39.4% | unknown | unknown | pending |
| 233_015 | multi_vector | Biotech/Longevity | Infinite longevity is coming for this generation of kids. | Peter Diamandis | 37.6% | unknown | unknown | pending |
| 245_037 | multi_vector | Biotech/Longevity | Mosquito gene drive halted in Africa was possibly wrong to stop since mosquitoes are part of the food web (but invasives are not) | Ben Lamm | 37.5% | unknown | unknown | pending |
| IND_020 | multi_vector | Biotech/Longevity | Massive 'rerating' of Biotech industry — by 2026, generative biology achieves its 'De Novo' moment where an AI-designed drug candidate triggers multi-billion-dollar partnerships; AI expands Total Addressable Market (TAM) of gene editing by 100x, moving... | Morgan Stanley | 36.1% | unknown | unknown | pending |
| 245_024 | multi_vector | Biotech/Longevity | Colossal gene editing will reach thousands of edits (up from current hundreds) | Ben Lamm | 34.2% | unknown | unknown | pending |
| IND_005 | multi_vector | Biotech/Longevity | Convergence of computational biology + AI-driven data modeling + CRISPR gene editing enables bringing back extinct species — Form Bio platform (spun out 2022) enables successful resurrection of woolly mammoth and Tasmanian tiger within the decade (by ~... | Ben Lamm | 32.5% | unknown | unknown | in_progress |
| 245_003 | multi_vector | Markets/Stocks | Colossal's $10B valuation is massively undervalued | Ben Lamm | 29.8% | unknown | unknown | pending |
Adverse scenarios (0)
Predictions where this ticker is displaced
| Pred | Domain | Prediction | Predictor | Current | Move | Impact | Mechanism |
|---|---|---|---|---|---|---|---|
| No adverse scenarios | |||||||